Compounds | Formula | Skin permeation value (log Kp) cm/s | GI absorption | BBB permeability | Inhibitor interaction (SwissADME/PreADMET) | |||||
---|---|---|---|---|---|---|---|---|---|---|
P-gp substrate | CYP1A2 | CYP2C19 | CYP2C9 | CYP2D6 | CYP3A4 | |||||
4 | C10H5ClFNO | − 5.65 | High | Yes | No | Yes | No | No | No | No |
5 | C11H8FNO2 | − 6.09 | High | Yes | No | Yes | No | No | No | No |
6 | C12H10FNO2 | − 5.92 | High | Yes | No | Yes | Yes | No | No | No |
7 | C12H6FNOS | − 5.37 | High | Yes | No | Yes | Yes | No | No | No |
8 | C10H5ClFNO2 | − 5.7 | High | Yes | No | No | No | No | No | No |
9 | C14H16FN3O2 | − 7.42 | High | No | Yes | No | No | No | No | No |
10 | C22H16FN3 | − 4.5 | High | No | No | Yes | Yes | No | Yes | Yes |
15 | C11H9NO2 | − 6.05 | High | Yes | No | Yes | No | No | No | No |
16 | C12H11NO3 | − 5.96 | High | Yes | No | Yes | No | No | No | No |
Vosaroxin | C18H19N5O4S | − 8.98 | High | No | Yes | Yes | No | No | No | No |